1. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027–1036.
2. Gorbach SL. Antibiotics and Clostridium difficle. N Engl J Med 1999;341:1690–1691.
3. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis.Infect Control Hosp Epidemiol 1995;16:459–477.
4. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334–339.
5. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162:2177–2184.
6. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
7. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678–674.
8. Modena S, Bearelly D, Swartz K, et al. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005;26:685–690.
9. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95–100.
10. Brown E, Talbot GH, Axelrod P, et al. Risk factors for Clostridium difficile toxin-associated diarrhea.Infect Control Hosp Epidemiol 1990;11:283–290.
11. Vesta KS, Wells PG, Gentry CA, et al. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control 2005;33:469–472.
12. Cooper GS, Lederman MM, Salata RA. A predictive model to identify Clostridium difficile toxin in hospitalized patients with diarrhea. Am J Gastroenterol 1996;91:80–84.
13. Kroker PB, Bower M, Azadian B. Clostridium difficile infection, hospital geography and time-space clustering. QJM 2001;94:223–225.
14. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005;26:672–675.
15. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1–15.
16. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis 1993;17:672–678.
17. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect2001;7:405–410.
18. Borriello SP, Wilcox MH. Clostridium difficile infections of the gut: the unanswered questions. J Antimicrob Chemother 1998;41(Suppl C):67–69.
19. Forward LJ, Tompkins DS, Brett MM. Detection of Clostridium difficile cytotoxin and Clostridium perfringens enterotoxin in cases of diarrhea in the community. J Med Microbiol 2003;52:753–757.
20. Palmore TN, Sohn S, Malak SE, et al. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680–684.
21. Johnson S, Clabots CR, Linn FV, et al. Nosocomial Clostridium difficile colonisation and disease.Lancet 1990;336:97–100.
22. Clabots CR, Johnson S, Olson MM, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561–567.
23. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204–210.
24. Borrielo SP. The influence of the normal flora on Clostridium difficile colonization of the gut. Ann Med1990;22:61–67.
25. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993;16(Suppl 4):S214–S218.
26. Nelson DE, Auerbach SB, Baltch AL, et al. Epidemic Clostridium difficile- associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88–94.
27. Zimmerman RK. Risk factors for Clostridium difficile cytotoxin-positive diarrhea after control for horizontal transmission. Infect Control Hosp Epidemiol 1991;12:96–100.
28. Golledge CL, McKenzie T, Riley TV. Extended spectrum cephalosporins and Clostridium difficile. J Antimicrob Chemother 1989;23:929–931.
29. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi- institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.
30. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene- variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.
31. Osler T, Lott D, Bordley J, et al. Cefazolin-induced pseudomembranous colitis resulting in perforation of the sigmoid colon. Dis Colon Rectum 1986;29:140–143.
32. McNeeley SG, Anderson GD, Sibai BM. Clostridium difficile colitis associated with single-dose cefazolin prophylaxis. Obstet Gynecol 1985;66:737–738.
33. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. J Antimicrob Chemother 1991;35:208–210.
34. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-asociated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.
35. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
36. McCusker ME, Harris AD, Perencevich E, et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730–733.
37. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. Tenn Med 2002;95:113–115.
38. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572–575.
39. Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006;26:61–67.
40. Khan R, Cheesebrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003;54:104–108.
41. Al-Eidan FA, McElnay JC, Scott MG, et al. Clostridium difficile-associated diarrhoea in hospitalized patients. J Clin Pharm Ther 2000;25:101–109.
42. Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile–associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012–1019.
43. Snell H, Ramos M, Longo S, et al. Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C difficile Tox A/B II EIA Kit, the Triage C difficile Panel Immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 2004;42:4863–4865.
44. Vanpoucke H, De Baere T, Claeys G, et al. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect2001;7:55–64.
45. Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol 2005;43:2994–2995.